Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 2Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Lymphoma, Extranodal NK-T-Cell 5Hodgkin Disease 5Recurrence 4Neuroblastoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Testicular Neoplasms 3Sezary Syndrome 3Neuroectodermal Tumors, Primitive, Peripheral 3Mycosis Fungoides 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Acute 3Leukemia, Hairy Cell 3Dendritic Cell Sarcoma, Interdigitating 3Central Nervous System Neoplasms 3Teratoma 2Sarcoma 2

Interventions

Tretinoin 3venetoclax 1Etoposide 1Daunorubicin 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Leukemia, Promyelocytic, Acute × Etoposide × Clear all
NCT05832320 2024-05-10

Optimum Induction Therapy of Low-risk APL

Peking University People's Hospital

Phase NA Unknown
74 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡